Keymed Biosciences Past Earnings Performance
Past criteria checks 0/6
Keymed Biosciences has been growing earnings at an average annual rate of 39%, while the Biotechs industry saw earnings growing at 11.7% annually. Revenues have been growing at an average rate of 78.8% per year.
Key information
39.0%
Earnings growth rate
98.6%
EPS growth rate
| Biotechs Industry Growth | 11.0% |
| Revenue growth rate | 78.8% |
| Return on equity | -12.0% |
| Net Margin | -101.5% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
There's Reason For Concern Over Keymed Biosciences Inc.'s (HKG:2162) Massive 28% Price Jump
May 13
News Flash: 10 Analysts Think Keymed Biosciences Inc. (HKG:2162) Earnings Are Under Threat
Apr 03Keymed Biosciences Inc. (HKG:2162) Just Reported And Analysts Have Been Cutting Their Estimates
Mar 31A Look At The Intrinsic Value Of Keymed Biosciences Inc. (HKG:2162)
Nov 13Analysts Just Made A Noticeable Upgrade To Their Keymed Biosciences Inc. (HKG:2162) Forecasts
Sep 03Broker Revenue Forecasts For Keymed Biosciences Inc. (HKG:2162) Are Surging Higher
Mar 21Companies Like Keymed Biosciences (HKG:2162) Are In A Position To Invest In Growth
Jun 27Revenue & Expenses Breakdown
How Keymed Biosciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 354 | -359 | 177 | 596 |
| 30 Sep 23 | 341 | -313 | 171 | 595 |
| 30 Jun 23 | 327 | -267 | 165 | 593 |
| 31 Mar 23 | 214 | -287 | 150 | 550 |
| 31 Dec 22 | 100 | -308 | 134 | 507 |
| 30 Sep 22 | 155 | -281 | 125 | 419 |
| 30 Jun 22 | 210 | -253 | 117 | 331 |
| 31 Mar 22 | 160 | -2,070 | 105 | 345 |
| 31 Dec 21 | 110 | -3,887 | 92 | 358 |
| 30 Sep 21 | 55 | -4,149 | 67 | 318 |
| 30 Jun 21 | 0 | -4,412 | 41 | 279 |
| 31 Mar 21 | 0 | -2,615 | 31 | 203 |
| 31 Dec 20 | 0 | -819 | 22 | 127 |
Quality Earnings: 2162 is currently unprofitable.
Growing Profit Margin: 2162 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 2162 is unprofitable, but has reduced losses over the past 5 years at a rate of 39% per year.
Accelerating Growth: Unable to compare 2162's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 2162 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (22.1%).
Return on Equity
High ROE: 2162 has a negative Return on Equity (-11.98%), as it is currently unprofitable.